Cargando…
Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency
Pathogen reduction technologies (PRT) have been recommended by many regulatory authorities to minimize the residual risk of transfusion-transmitted infections associated with COVID19 convalescent plasma. While its impact on safety and its cost-effectiveness are nowadays well proven, there is theoret...
Autores principales: | Focosi, D., Franchini, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927574/ https://www.ncbi.nlm.nih.gov/pubmed/33675992 http://dx.doi.org/10.1016/j.tracli.2021.02.005 |
Ejemplares similares
-
WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
por: Franchini, Massimo, et al.
Publicado: (2023) -
Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2022) -
Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe
por: Focosi, Daniele, et al.
Publicado: (2022) -
Assessment of the impact of pathogen reduction technologies on the neutralizing activity of COVID-19 convalescent plasma.
por: Hindawi, Salwa, et al.
Publicado: (2023) -
Convalescent plasma for COVID-19. TSUNAMI is not the final word
por: Franchini, Massimo, et al.
Publicado: (2022)